ChromaDex Corp. (CDXC)
Chromadex Corp. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.
Address
10900 WILSHIRE BLVD
LOS ANGELES, CA 90024
Founded
1999
Number of Employees
106
Website
http://www.chromadex.com
Buyback
Buyback Data | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
---|---|---|---|---|---|---|---|---|---|---|---|---|
$ Amount Purchased ($ in 000s ) |
- | - | - | $405 | - | - | - | - | - | - | - | $405 |
Average Price | - | - | - | $5.44 | - | - | - | - | - | - | - | $5.44 |
# Shares Purchased | - | - | - | 74,379 | - | - | - | - | - | - | - | 74,379 |
Buyback Performance | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Return to Date | - | - | - | -44.9% | - | - | - | - | - | - | - | -44.9% |
S&P 500 Return to Date | - | - | - | 129.7% | - | - | - | - | - | - | - | 129.7% |
Excess Total Return | - | - | - | -174.6% | - | - | - | - | - | - | - | -174.6% |
Quartile Rank |
|
|
|
|
|
|
|
|
|
|
|
|
Percentile Rank | - | - | - | 17% | - | - | - | - | - | - | - | 16% |
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)